PersonalisPSNL
Market Cap: $354M
About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Employees: 225
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2.07% less ownership
Funds ownership: 44.34% [Q1] → 42.27% (-2.07%) [Q2]
3% less funds holding
Funds holding: 71 [Q1] → 69 (-2) [Q2]
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
23% less capital invested
Capital invested by funds: $33.4M [Q1] → $25.7M (-$7.67M) [Q2]
63% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 30
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 49 / 135 met price target | 68%upside $9 | Buy Maintained | 19 Aug 2024 |
BTIG Mark Massaro 63% 1-year accuracy 17 / 27 met price target | 30%upside $7 | Buy Maintained | 16 Aug 2024 |
Needham Mike Matson 64% 1-year accuracy 45 / 70 met price target | 35%upside $7.25 | Buy Maintained | 16 Aug 2024 |
Needham Mike Matson 64% 1-year accuracy 45 / 70 met price target | 35%downside $3.50 | Buy Reiterated | 21 Jun 2024 |
Financial journalist opinion
Based on 4 articles about PSNL published over the past 30 days